Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) insider Charles Schoch sold 5,000 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $8.83, for a total value of $44,150.00. Following the transaction, the insider now directly owns 38,038 shares of the company's stock, valued at approximately $335,875.54. This trade represents a 11.62 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Candel Therapeutics Stock Performance
Shares of NASDAQ:CADL opened at $8.90 on Thursday. Candel Therapeutics, Inc. has a 52-week low of $1.40 and a 52-week high of $14.60. The stock has a 50 day moving average price of $8.23 and a 200-day moving average price of $7.00. The firm has a market capitalization of $289.04 million, a P/E ratio of -5.14 and a beta of -1.29.
Candel Therapeutics (NASDAQ:CADL - Get Free Report) last posted its earnings results on Thursday, March 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.17). On average, equities analysts forecast that Candel Therapeutics, Inc. will post -1.47 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on the company. Canaccord Genuity Group lifted their price target on Candel Therapeutics from $20.00 to $25.00 and gave the stock a "buy" rating in a report on Wednesday, February 26th. Citigroup assumed coverage on Candel Therapeutics in a report on Thursday, February 20th. They issued a "buy" rating and a $25.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $19.00 target price on shares of Candel Therapeutics in a report on Friday, March 14th. Finally, Bank of America began coverage on shares of Candel Therapeutics in a research note on Friday, February 7th. They issued a "buy" rating and a $15.00 price objective on the stock.
Get Our Latest Stock Report on CADL
Hedge Funds Weigh In On Candel Therapeutics
Several institutional investors have recently bought and sold shares of CADL. Baker BROS. Advisors LP bought a new stake in Candel Therapeutics during the 4th quarter valued at about $25,884,000. Acorn Capital Advisors LLC purchased a new position in shares of Candel Therapeutics in the fourth quarter worth $16,836,000. Braidwell LP purchased a new position in Candel Therapeutics in the 4th quarter worth $13,888,000. Portolan Capital Management LLC acquired a new stake in shares of Candel Therapeutics in the fourth quarter worth $6,543,000. Finally, Halter Ferguson Financial Inc. raised its stake in shares of Candel Therapeutics by 123.7% during the 4th quarter. Halter Ferguson Financial Inc. now owns 681,334 shares of the company's stock valued at $5,914,000 after buying an additional 376,795 shares during the last quarter. Institutional investors own 13.93% of the company's stock.
About Candel Therapeutics
(
Get Free Report)
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
